Positron emission tomography (PET) in oncology (Part I);La tomografía por emisión de positrones (PET) en oncología (Parte I)

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 1, 2002, Pages 41-60

  Gamez Cenzano C ^a   Cabrera Villegas, A ^b   Sopena Monforte, R ^c   Garcia Velloso Ma J ^d  

^a Centro Andaluz de Diagnóstico PET   (Spain)

^b Unidad PET   (Spain)

^c Hospital 9 de Octubre   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 AMINO 2 METHYLPROPIONIC ACID C 11; 6 FLUORODOPA F 18; AMINOCYCLOBUTANECARBOXYLIC ACID C 11; AMMONIA N 13; ASPARTIC ACID C 11; CARBON DIOXIDE O 15; CISPLATIN N 13; FLOXURIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROPROLINE F 18; FLUOROURACIL F 18; GALLIUM EDETATE GA 68; GLUCOSE TRANSPORTER; GLUTAMIC ACID C 11; GLUTAMIC ACID N 13; GLUTAMINE C 11; METHIONINE C 11; POLYAMINE; PUTRESCINE C 11; PYRUVALDEHYDE BIS N 4 METHYLTHIOSEMICARBAZONE CU 62; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; TEMOZOLOMIDE C 11; THYMIDINE C 11; TYROSINE C 11; TYROSINE F 18; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER O 15; CARBON; DIAGNOSTIC AGENT; FLUORINE; GLUCOSE TRANSPORTER 1; METHIONINE; SLC2A1 PROTEIN, HUMAN; TUMOR PROTEIN;

ABDOMEN; CANCER; CANCER LOCALIZATION; CANCER SCINTISCANNING; DRUG ACCUMULATION; DRUG METABOLISM; DRUG UPTAKE; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; IMAGE PROCESSING; PELVIS; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE DIAGNOSIS; RADIOISOTOPE DISTRIBUTION; REVIEW; THORAX; TISSUE DISTRIBUTION; ANIMAL; BONE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; ENERGY METABOLISM; HEAD; METABOLISM; MOUSE; MUSCLE; NEOPLASM; SCINTISCANNING; THYROID GLAND;

ABDOMEN; ANIMALS; BONE AND BONES; CARBON RADIOISOTOPES; DIAGNOSIS, DIFFERENTIAL; ENERGY METABOLISM; FASTING; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HEAD; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; METHIONINE; MICE; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLES; NEOPLASM PROTEINS; NEOPLASMS; PELVIS; RADIOPHARMACEUTICALS; THORAX; THYROID GLAND; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038582645     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(02)72033-8     Document Type: Review

References (78)

1. Richter JA, Martí JM. PET. Tomografía molecular. Fundamentos y aplicaciones. Madrid. Ed. Eseuve, 1993.
2. Beany RP. Positron emission tomography in the study of human tumors. Sem Nucl Med 1984;14:324-41.
3. Silverman DHS, Hoh CK, Seltzer MA, Schiepers C, Cuan GS, Gambir SS, et al. Evaluating Tumor Biology and Oncological Disease with Positron Emission Tomography. Seminars in Radiation Oncology 1998;3:183-96.
4. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, et al. PET cancer evaluations with FDG. J Nucl Med 1991;32(8):1555-8.
5. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncologic applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
6. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37(7):1180-2.
7. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of Malignant Tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001;220:54-62.
8. 18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27(5):542-9.
9. 18F]Fluoro-L-Proline in Urologic Tumors. J Nucl Med 2001;42:752-4.
10. Mineura K, Yasuda T, Kowada M, Shishido F, Ogawa T, Uemura K. Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurol Res 1986;8(3):164-8.
11. 82Rb PET. J Comput Assist Tomogr 1987;11:563-70.
12. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36(2):417-28.
13. Le FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, et al. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-Grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764-9.
14. Mintum MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169(1):45-8.
15. 18F]Fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42:679-84.
16. Price P, Newell DR, Connors T, Harte R, Wells P, Brock C, et al. The potential of tracer kinetic studies in drug development programs: a new investigational area for cancer research (meeting abstract). Ann Oncol 1996;7(Supl 1):24.
17. Weber G, Cantero A. Glucose-6-phophastase activity in normal, precancerous and neoplastic tissues. Cancer Res 1955;15:105-8.
18. Warburg O. The metabolism of tumors, New York, Richard R. Smith, Inc.; 1931:129-69.
19. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988;263:1365-62.
20. Wahl RL. Clinical Oncology update: the emerging role of PET: part I. En: De Vita VT, Hellman S, Rosenberg SA, eds. Filadelfia: Lippincott-Raven 1997;11(2):1-24.
21. Brown RS, Whal RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study Cancer 1993;72:2979-85.
22. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344-8.
23. Farina FA, Adelman RC, Lo CH, Morris HP, Weinhouse S. Metabolic regulation and enzyme alterations in the Morris hepatomas. Cancer Res 1968;28:1897-900.
24. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation and growth rates of transplanted rat tumor. Cancer Res 1970;30:2240-4.
25. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med and Biol 1994;21:739-47.
26. 18F]-FDG in oncology: a clinical update. Nuclear Medicine and Biology 1996;23:717-35.
27. Lomeña F, Gámez C, Cabrera A, Maldonado A, Jiménez A. PET en oncología. Rev Esp Med Nuclear 2000;19(7):510-24.
28. 18F-FDG uptake in the differentiation of low-grade from-high-grade brain tumors with PET. Radiology 1995;195:47-52.
29. Gámez Cenzano C. Utilidad diagnóstica de la tomografía de positrones en la evaluación de los gliomas. Revista de Oncología 2000;2:3-11.
30. Rodríguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignance grade with PET in Non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
31. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32:1508-12.
32. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The rose of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-91.
33. Schifter T, Hoffman JM, Hanson MW, Boyko OK, Beam C, Paine S, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993;17(4):509-61.
34. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon PL, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
35. Higashi K, Clavo AC, Wahl RL, Does FDG uptake measure proliferative rate of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated Thymidine uptake. J Nucl Med 1993;34:414-9.
36. Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, DiChiro G. Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 1993;189(1):221-5.
37. 18F-fluoro-deoxy-glucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography. J Nucl Med 1992;33:1972-80.
38. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in Sarcoidosis. J Nucl Med 1994;35(10):1647-9.
39. 18]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990;14(3):486-7.
40. Dethy S, Goldman S, Blecis S, Luxen A, Levivier M, Hildebrand J, et al. 11C-methionine and fluorine-18 FDG PET study in brain hematoma. J Nucl Med 1994;35:1162-6.
41. Lindholm P, Leskinen KS, Grenman R, et al. Evaluation of response to radiotherapy in head and neck by PET and [11C] methionine. Inter J Radiat Oncol Biol Physics 1995;32:787-94.
42. Meyer GJ, Schober O, Hundeshagen H. Uptake of 11C-L- and D-methionine in brain tumors. Eur J Med 1985;10(7-8):373-6.
43. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50(5):1316-22.
44. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995;36:484-92.
45. Weber W, Voll B, Treumann T, Watzlowik P, Präuer H, Schwaiger M. Positronen-Emissions-Tomographie mit C-11-methionin und F-18-fluordeoxyglukose in der Diagnostik des brochialkarzinoms. Nuklearmedizin 1998;37:A37.
46. Ishii K, Ogawa T, Hatazawa J, Kanno I, Inugami A, Fujita H, et al. High L-methyl-[11C]methionine uptake in brain abscess: a PET study. J Comput Assist Tomogr 1993;17(4):660-1.
47. Meyer GJ, Schober O, Hundeshagen H. Uptake of 11C-L- and D-methionine in brain tumors. Eur J Nucl Med 1985;10(7-8):373-6.
48. Bergstrom M, Lundquist H, Ericson K, Lilja A, Johnstrom P, Langstrom B, et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987;28(3):225-9.
49. Kubota K, Yamada K, Fukada H, Endo S, Ito M, Abe Y, et al. Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med 1984;9(3):136-40.
50. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990;31(3):337-42.
51. Vander-Borght T, Pauwels S, Lambotte L, Labar D, De-Maeght S, Stroobandt G, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994;35(6):974-82.
52. 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982;23:63-74.
53. Thiel A, Herholz K, von-Stockhausen HM, van-Leyen-Pilgram K, Piertzyk U, Kessler J, et al. Localization of language-related cortex with 15O-labeled water PET in patients with gliomas. Neuroimage 1998;7(4 Pt 1):284-95.
54. Andrich MP, Neumann R. The role of PET imaging in early assessment of the anti-tumor impact of biologics and cytotoxics. Curr Opinion Oncol 1994;6:627-37.
55. Brock CS, Matthews JC, Brown G, Osman S, Luthra SK, Brady-F-Newlands ES, et al. Temozolomide uptake in human astrocytomas demonstrated in vivo (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997;16:A812.
56. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
57. Inoue T, Kim EE, Komaki R, Wong F, Bassa P, Wong W, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-93.
58. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi T. Microautoradiography study for differentiation of intratumoral macrophages, granulation tissues and cancer cells by dynamics of fluorine-18- fluordeoxyglucose uptake. J Nucl Med 1994;35:104-12.
59. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-20.
60. Erasmus JJ, McAdams HP, Patz EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-73.
61. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000;174(4):1005-8.
62. Avril N, Schelling M, Dose J, Menzel M, Weber W, Schwaiger M. Utility of PET in breast cancer. Clin Positron Imaging 1999;2:261-71.
63. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
64. Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104-9.
65. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med 1998;39(7):1302-5.
66. Valk PE. Sense and sensitivity: issues in technology assessment [editorial]. J Nucl Med 1996;37:1436-7.
67. 18F]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-50.
68. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med and Biol 1994;21:739-47.
69. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890-4.
70. Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
71. Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluoro-deoxyglucose utilization: a re-examination. J Nucl Med 1996;37: 394-9.
72. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26:308-14.
73. Engel H, Steinert H, Buck A, Berthold T, Böñi RA, Van Schulthess GK. Wholebody PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996;37: 441-6.
74. Stadalnik RC. Benign causes of 18-FDG uptake on whole body imaging. Sem Nucl Med 1998;28:352-8.
75. Bujenovic S, Boggs R, Beven T, Sylvester JM. Total body FDG-PET: avoiding pitfalls in acquisition and interpretation (abstract). Clin Nucl Med 1997;22:200.
76. 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591-5.
77. Yun M, Yeh D, Araújo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26(4):314-9.
78. Hautzel H, Muller GH. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384-6.